Michael Zasloff
Michael Zasloff has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Denise Barbut
BAZ Therapeutics, Inc., Philadelphia, USA
8 shared publications- Michele Vendruscolo
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
4 shared publications - Ryan Limbocker
Department of Chemical and Biological Science and Engineering
4 shared publications - Denise Barbut
Enterin, Inc., Philadelphia, PA, USA
3 shared publications - Fabrizio Chiti
University of Florence
3 shared publications - Tuomas P. J. Knowles
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Squalamine prevents motor and non-motor symptoms in the paraquat and lectin rat model of the body-first subtype of Parkinson's disease
Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S 129 -α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S 129 -α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.
- 6 November 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Open AccessSqualamine prevents motor and non-motor symptoms in the paraquat and lectin rat model of the body-first subtype of Parkinson's disease
Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S 129 -α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S 129 -α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.
- Open Access
- 28 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (44)
Prioritize validation over discovery of novel antibiotics
Prioritize validation over discovery of novel antibiotics
- 28 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (44)
Open AccessPrioritize validation over discovery of novel antibiotics
Prioritize validation over discovery of novel antibiotics
- Open Access
- 19 December 2024
- Published by Springer Nature in npj Aging
- Vol. 10 (1) , 1-10
Anti-aging properties of the aminosterols of the dogfish shark
The development of anti-aging drugs is challenged by both the apparent complexity of the physiological mechanisms involved in aging and the likelihood that many of these mechanisms remain unknown. As a consequence, the development of anti-aging compounds based on the rational targeting of specific pathways has fallen short of the goal. To date, the most impressive compound is rapamycin, a natural bacterial product initially identified as an antifungal, and only subsequently discovered to have anti-aging properties. In this review, we focus on two aminosterols from the dogfish shark, Squalus acanthias, that we discovered initially as broad-spectrum anti-microbial agents. This review is the first to gather together published studies conducted both in vitro and in numerous vertebrate species to demonstrate that these compounds target aging pathways at the cellular level and provide benefits in multiple aging-associated conditions in relevant animal models and in humans. The dogfish aminosterols should be recognized as potential anti-aging drugs.
- 19 December 2024
- Published by Springer Nature in npj Aging
- Vol. 10 (1) , 1-10
Open AccessAnti-aging properties of the aminosterols of the dogfish shark
The development of anti-aging drugs is challenged by both the apparent complexity of the physiological mechanisms involved in aging and the likelihood that many of these mechanisms remain unknown. As a consequence, the development of anti-aging compounds based on the rational targeting of specific pathways has fallen short of the goal. To date, the most impressive compound is rapamycin, a natural bacterial product initially identified as an antifungal, and only subsequently discovered to have anti-aging properties. In this review, we focus on two aminosterols from the dogfish shark, Squalus acanthias, that we discovered initially as broad-spectrum anti-microbial agents. This review is the first to gather together published studies conducted both in vitro and in numerous vertebrate species to demonstrate that these compounds target aging pathways at the cellular level and provide benefits in multiple aging-associated conditions in relevant animal models and in humans. The dogfish aminosterols should be recognized as potential anti-aging drugs.
- Open Access
- 22 September 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 5701-5712
A novel, centrally acting mammalian aminosterol, ENT ‐03, induces weight loss in obese and lean rodents
ENT‐03, a spermine bile acid we recently discovered in the brain of newborn mice acts centrally to regulate energy and metabolism. Obese, diabetic (ob/ob) mice treated with five doses of ENT‐03 over 2 weeks, demonstrated a rapid decrease in blood glucose levels into the range seen in non‐obese animals, prior to any significant weight loss. Weight fell substantially thereafter as food intake decreased, and serum biochemical parameters normalized compared with both vehicle and pair‐fed controls. To determine whether ENT‐03 could be acting centrally, we injected a single dose of ENT‐03 intracerebroventricularly to Sprague–Dawley rats. Weight fell significantly and remained below vehicle injected controls for an extended period. By autoradiography, ENT‐03 localized to the arcuate nucleus of the hypothalamus, the choroid plexus and cerebrospinal fluid. Significant cFos activation occurred in multiple anatomical regions within the hypothalamus and brainstem involved in appetite suppression, food‐entrained circadian rhythmicity, autonomic function, and growth. These data support a role for ENT‐03 in the treatment of type 2 diabetes and obesity. Phase 1 studies in subjects with obesity and diabetes are currently in progress.
- 22 September 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 5701-5712
Open AccessA novel, centrally acting mammalian aminosterol, ENT ‐03, induces weight loss in obese and lean rodents
ENT‐03, a spermine bile acid we recently discovered in the brain of newborn mice acts centrally to regulate energy and metabolism. Obese, diabetic (ob/ob) mice treated with five doses of ENT‐03 over 2 weeks, demonstrated a rapid decrease in blood glucose levels into the range seen in non‐obese animals, prior to any significant weight loss. Weight fell substantially thereafter as food intake decreased, and serum biochemical parameters normalized compared with both vehicle and pair‐fed controls. To determine whether ENT‐03 could be acting centrally, we injected a single dose of ENT‐03 intracerebroventricularly to Sprague–Dawley rats. Weight fell significantly and remained below vehicle injected controls for an extended period. By autoradiography, ENT‐03 localized to the arcuate nucleus of the hypothalamus, the choroid plexus and cerebrospinal fluid. Significant cFos activation occurred in multiple anatomical regions within the hypothalamus and brainstem involved in appetite suppression, food‐entrained circadian rhythmicity, autonomic function, and growth. These data support a role for ENT‐03 in the treatment of type 2 diabetes and obesity. Phase 1 studies in subjects with obesity and diabetes are currently in progress.
- 21 May 2024
- Published by Elsevier in Trends in Microbiology
- Vol. 32 (7) , 624-627
Influence of antimicrobial peptides on the bacterial membrane curvature and vice versa
- 21 May 2024
- Published by Elsevier in Trends in Microbiology
- Vol. 32 (7) , 624-627
Influence of antimicrobial peptides on the bacterial membrane curvature and vice versa
- Open Access
- 10 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-13
Squalamine reverses age-associated changes of firing patterns of myenteric sensory neurons and vagal fibres
Vagus nerve signaling is a key component of the gut-brain axis and regulates diverse physiological processes that decline with age. Gut to brain vagus firing patterns are regulated by myenteric intrinsic primary afferent neuron (IPAN) to vagus neurotransmission. It remains unclear how IPANs or the afferent vagus age functionally. Here we identified a distinct ageing code in gut to brain neurotransmission defined by consistent differences in firing rates, burst durations, interburst and intraburst firing intervals of IPANs and the vagus, when comparing young and aged neurons. The aminosterol squalamine changed aged neurons firing patterns to a young phenotype. In contrast to young neurons, sertraline failed to increase firing rates in the aged vagus whereas squalamine was effective. These results may have implications for improved treatments involving pharmacological and electrical stimulation of the vagus for age-related mood and other disorders. For example, oral squalamine might be substituted for or added to sertraline for the aged.
- 10 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-13
Open AccessSqualamine reverses age-associated changes of firing patterns of myenteric sensory neurons and vagal fibres
Vagus nerve signaling is a key component of the gut-brain axis and regulates diverse physiological processes that decline with age. Gut to brain vagus firing patterns are regulated by myenteric intrinsic primary afferent neuron (IPAN) to vagus neurotransmission. It remains unclear how IPANs or the afferent vagus age functionally. Here we identified a distinct ageing code in gut to brain neurotransmission defined by consistent differences in firing rates, burst durations, interburst and intraburst firing intervals of IPANs and the vagus, when comparing young and aged neurons. The aminosterol squalamine changed aged neurons firing patterns to a young phenotype. In contrast to young neurons, sertraline failed to increase firing rates in the aged vagus whereas squalamine was effective. These results may have implications for improved treatments involving pharmacological and electrical stimulation of the vagus for age-related mood and other disorders. For example, oral squalamine might be substituted for or added to sertraline for the aged.
- Open Access
- 5 May 2023
- Published by Springer Nature in Research Square
Gut-Brain rejuvenation: Identification of age associated changes in the neural firing pattern of myenteric primary afferent neurons and vagal fibres that are reversed by the aminosterol, squalamine
Vagus nerve signaling is a key component of the gut-brain axis and regulates diverse physiological processes that decline with age. Gut to brain vagus firing patterns are regulated by myenteric intrinsic primary afferent neuron (IPAN) to vagus neurotransmission. It remains unclear how IPANs or the afferent vagus age functionally. Here we identified a distinct ageing code in gut to brain neurotransmission defined by consistent differences in firing rates, burst durations, interburst and intraburst firing intervals of IPANs and the vagus, when comparing young and aged neurons. The aminosterol, squalamine, reverted aged neurons to a young phenotype indicating the age associated changes in neural firing patterns are reversable. In contrast to young neurons sertraline failed to increase firing rates in the aged vagus whereas squalamine was still effective. These results may have implications for improved treatments involving pharmacological and electrical stimulation of the vagus for age-related mood and other disorders.
- 5 May 2023
- Published by Springer Nature in Research Square
Open AccessGut-Brain rejuvenation: Identification of age associated changes in the neural firing pattern of myenteric primary afferent neurons and vagal fibres that are reversed by the aminosterol, squalamine
Vagus nerve signaling is a key component of the gut-brain axis and regulates diverse physiological processes that decline with age. Gut to brain vagus firing patterns are regulated by myenteric intrinsic primary afferent neuron (IPAN) to vagus neurotransmission. It remains unclear how IPANs or the afferent vagus age functionally. Here we identified a distinct ageing code in gut to brain neurotransmission defined by consistent differences in firing rates, burst durations, interburst and intraburst firing intervals of IPANs and the vagus, when comparing young and aged neurons. The aminosterol, squalamine, reverted aged neurons to a young phenotype indicating the age associated changes in neural firing patterns are reversable. In contrast to young neurons sertraline failed to increase firing rates in the aged vagus whereas squalamine was still effective. These results may have implications for improved treatments involving pharmacological and electrical stimulation of the vagus for age-related mood and other disorders.
- 1 December 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (12) , 1666-1674
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease
Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study in pat... Visual ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease. Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhi... Background: Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label ...
- 1 December 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (12) , 1666-1674
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease
Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study in pat... Visual ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease. Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhi... Background: Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label ...
- Open Access
- 25 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2079
The Microbiome and Metabolomic Profile of the Transplanted Intestine with Long-Term Function
We analyzed the fecal microbiome by deep sequencing of the 16S ribosomal genes and the metabolomic profiles of 43 intestinal transplant recipients to identify biomarkers of graft function. Stool samples were collected from 23 patients with stable graft function five years or longer after transplant, 15 stable recipients one-year post-transplant and four recipients with refractory rejection and graft loss within one-year post-transplant. Lactobacillus and Streptococcus species were predominant in patients with stable graft function both in the short and long term, with a microbiome profile consistent with the general population. Conversely, Enterococcus species were predominant in patients with refractory rejection as compared to the general population, indicating profound dysbiosis in the context of graft dysfunction. Metabolomic analysis demonstrated significant differences between the three groups, with several metabolites in rejecting recipients clustering as a distinct set. Our study suggests that the bacterial microbiome profile of stable intestinal transplants is similar to the general population, supporting further application of this non-invasive approach to identify biomarkers of intestinal graft function.
- 25 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (9) , 2079
Open AccessThe Microbiome and Metabolomic Profile of the Transplanted Intestine with Long-Term Function
We analyzed the fecal microbiome by deep sequencing of the 16S ribosomal genes and the metabolomic profiles of 43 intestinal transplant recipients to identify biomarkers of graft function. Stool samples were collected from 23 patients with stable graft function five years or longer after transplant, 15 stable recipients one-year post-transplant and four recipients with refractory rejection and graft loss within one-year post-transplant. Lactobacillus and Streptococcus species were predominant in patients with stable graft function both in the short and long term, with a microbiome profile consistent with the general population. Conversely, Enterococcus species were predominant in patients with refractory rejection as compared to the general population, indicating profound dysbiosis in the context of graft dysfunction. Metabolomic analysis demonstrated significant differences between the three groups, with several metabolites in rejecting recipients clustering as a distinct set. Our study suggests that the bacterial microbiome profile of stable intestinal transplants is similar to the general population, supporting further application of this non-invasive approach to identify biomarkers of intestinal graft function.
- Open Access
- 11 April 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (8) , 1219-1231
A Brain-Permeable Aminosterol Regulates Cell Membranes to Mitigate the Toxicity of Diverse Pore-Forming Agents
The molecular composition of the plasma membrane plays a key role in mediating the susceptibility of cells to perturbations induced by toxic molecules. The pharmacological regulation of the properties of the cell membrane has therefore the potential to enhance cellular resilience to a wide variety of chemical and biological compounds. In this study, we investigate the ability of claramine, a blood–brain barrier permeable small molecule in the aminosterol class, to neutralize the toxicity of acute biological threat agents, including melittin from honeybee venom and α-hemolysin from Staphylococcus aureus. Our results show that claramine neutralizes the toxicity of these pore-forming agents by preventing their interactions with cell membranes without perturbing their structures in a detectable manner. We thus demonstrate that the exogenous administration of an aminosterol can tune the properties of lipid membranes and protect cells from diverse biotoxins, including not just misfolded protein oligomers as previously shown but also biological protein-based toxins. Our results indicate that the investigation of regulators of the physicochemical properties of cell membranes offers novel opportunities to develop countermeasures against an extensive set of cytotoxic effects associated with cell membrane disruption.
- 11 April 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (8) , 1219-1231
Open AccessA Brain-Permeable Aminosterol Regulates Cell Membranes to Mitigate the Toxicity of Diverse Pore-Forming Agents
The molecular composition of the plasma membrane plays a key role in mediating the susceptibility of cells to perturbations induced by toxic molecules. The pharmacological regulation of the properties of the cell membrane has therefore the potential to enhance cellular resilience to a wide variety of chemical and biological compounds. In this study, we investigate the ability of claramine, a blood–brain barrier permeable small molecule in the aminosterol class, to neutralize the toxicity of acute biological threat agents, including melittin from honeybee venom and α-hemolysin from Staphylococcus aureus. Our results show that claramine neutralizes the toxicity of these pore-forming agents by preventing their interactions with cell membranes without perturbing their structures in a detectable manner. We thus demonstrate that the exogenous administration of an aminosterol can tune the properties of lipid membranes and protect cells from diverse biotoxins, including not just misfolded protein oligomers as previously shown but also biological protein-based toxins. Our results indicate that the investigation of regulators of the physicochemical properties of cell membranes offers novel opportunities to develop countermeasures against an extensive set of cytotoxic effects associated with cell membrane disruption.